Cannabidivarin

Cannabidivarin

SCHEMBL243338

C=C(C)[C@H]1CCC(C)=C[C@@H]1c1c(O)cc(CCC)cc1O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 12/20 1.00
CNR1 P21554 11/20 1.00
OPRM1 P35372 7/20 1.00
GPR55 Q9Y2T6 4/20 1.00
TRPV1 Q8NER1 3/20 1.00
CYP1A1 P04798 2/20 1.00
CYP2D6 P10635 2/20 1.00
CYP2B6 P20813 2/20 1.00
SLC6A2 P23975 2/20 1.00
CYP2C19 P33261 2/20 1.00
SLC6A3 Q01959 2/20 1.00
TRPM8 Q7Z2W7 2/20 1.00
TRPA1 O75762 1/20 1.00
GPR6 P46095 1/20 1.00
NAAA Q02083 1/20 1.00
TRPV3 Q8NET8 1/20 1.00
TRPV4 Q9HBA0 1/20 1.00
DAGLA Q9Y4D2 1/20 1.00
TRPV2 Q9Y5S1 1/20 1.00
MLNR O43193 1/20 0.84

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cannabidivarin SCHEMBL22705595 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL18371742 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL17345387 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL2759238 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL16224876 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL19477708 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL6857317 1.00 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
Cannabidivarin SCHEMBL10296698 0.93 CNR2 (0.86) CNR2CNR1OPRM1GPR55TRPV1
SCHEMBL23686658 0.92 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1
SCHEMBL22705457 0.92 CNR2 (1.00) CNR2CNR1OPRM1GPR55TRPV1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 10142 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144805-A1 CANNABIDIOL COMPOSITIONS FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND NEUROLOGICAL DISORDERS JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) 2026-05-28 US claimed
EP-4412609-B1 ALKOXYLATION OF CANNABIDIOL & OTHER CANNABINOIDS INDORAMA VENTURES OXIDES LLC (US) 2026-05-27 EP claimed
US-12636251-B1 Glycoside-containing aqueous formulations having a lipophilic active component Doane Technology Group LLC (US) 2026-05-26 US claimed
US-20260137705-A1 NOVEL CANNABINOID NANOPARTICLE COMPOSITIONS FOR THERAPEUTIC APPLICATIONS IN VETERINARY MEDICINE Chou2 Pharma LLC (US) 2026-05-21 US claimed
US-12629332-B2 Cannabinoid chewing gum with sugar alcohols NORDICCAN A/S (DK) 2026-05-19 US claimed
EP-4740961-A2 CANNABINOID PRODUCT FOR IMPROVING MUSCULOSKELETAL HEALTH Lonza Greenwood LLC (US) 2026-05-13 EP claimed
EP-4739284-A1 AN ADHESIVE ORAL DISC FOR SUSTAINED RELEASE OF CANNABINOIDS Fertin Pharma A/S (DK) 2026-05-13 EP claimed
EP-4291170-B1 USE OF CANNABIDIVARIN IN THE TREATMENT OF SEIZURES ASSOCIATED WITH CANINE EPILEPSY JAZZ PHARMACEUTICALS RESEARCH UK LTD (GB) 2026-05-13 EP claimed
EP-4734961-A1 NEW METHOD OF PRODUCING AN AQUEOUS MESOPARTICLE COMPOSITION COMPRISING A LIPOPHILIC COMPOUND BIOGNTX R&D B.V. (NL) 2026-05-06 EP claimed
US-12616728-B2 Processes and systems for converting cannabinoids into cannabinoid derivatives and isolating the same SUPER CRITICAL IP, LLC (US) 2026-05-05 US claimed
WO-2005120478-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASE AND/OR SYMPTOMS IN ARTHRITIS GW PHARMA LIMITED (GB) 2005-12-22 WO claimed
CN-1688290-A Cannabinoid liquid formulations for mucosal amdinistration GW PHARMA LTD (GB) 2005-10-26 CN claimed
US-6946150-B2 Lipophilic medicament, a solvent and a co-solvent in an amount > 55% wt/wt of the formulation; free from self emulsifying agent and/or a fluorinated propellant; cannabinoids administered by a pump action spray GW PHARMA LIMITED (GB) 2005-09-20 US claimed
EP-1542657-A1 CANNABINOID LIQUID FORMULATIONS FOR MUCOSAL AMDINISTRATION GW Pharma Limited (GB) 2005-06-22 EP claimed
US-20040192760-A1 Applying lipophilic drug to surface of mucous membrane; sustained release; cannabis compound mixture; inflammatory bowel disorders; Croh's disease; analgesics; control oxidation stresses; appetites ;anticancer agents U.S. BANK NATIONAL ASSOCIATION 2004-09-30 US claimed
WO-2004016246-A1 CANNABINOID LIQUID FORMULATIONS FOR MUCOSAL AMDINISTRATION GW PHARMA LIMITED (GB) 2004-02-26 WO claimed
US-20040034108-A1 Lipophilic medicament, a solvent and a co-solvent in an amount > 55% wt/wt of the formulation; free from self emulsifying agent and/or a fluorinated propellant; cannabinoids administered by a pump action spray U.S. BANK NATIONAL ASSOCIATION 2004-02-19 US claimed
EP-1361864-A2 MUCOADHESIVE PHARMACEUTICAL FORMULATIONS GW Pharma Limited (GB) 2003-11-19 EP claimed
US-20030021752-A1 Pharmaceutical formulations GW PHARMA LIMITED (GB) 2003-01-30 US claimed
WO-2002064109-A2 MUCOADHESIVE PHARMACEUTICAL FORMULATIONS GW PHARMA LIMITED (GB) 2002-08-22 WO claimed